Bcl-2与布鲁顿酪氨酸激酶抑制剂协同消除弥漫性大B细胞淋巴瘤体外及原位异种移植模型中的生长
研究通过单药及联合药物反应谱分析发现,维奈克拉与依鲁替尼联合可有效杀伤弥漫性大B细胞淋巴瘤细胞,其疗效与Bcl-2高表达及慢性活跃BCR信号相关;原位异种移植和患者来源异种移植模型证实联合治疗优于单药,并可克服维奈克拉原发性和获得性耐药;瑞士队列中约15%患者基于Bcl-2高表达和核NF-κB定位预测对联合治疗有反应。
要点
- 维奈克拉与依鲁替尼联合在体外有效杀伤弥漫性大B细胞淋巴瘤细胞。
- Bcl-2高表达(BCL2扩增或易位)联合慢性活跃BCR信号可准确预测双抑制反应。
- 联合治疗在异种移植模型中优于单药,并可克服维奈克拉原发性和获得性耐药。
核心结论
- 药物反应谱揭示的药物敏感性与特定突变特征及免疫组化生物标志物相关,联合Bcl-2/BTK抑制是弥漫性大B细胞淋巴瘤有前景的治疗策略。
研究设计与样本
- 研究采用单药及联合药物反应谱分析,并在原位异种移植和患者来源异种移植模型中进行验证,另分析瑞士弥漫性大B细胞淋巴瘤队列。
主要发现
- 维奈克拉与依鲁替尼联合在体外有效杀伤弥漫性大B细胞淋巴瘤细胞。
- BCL2扩增或易位所致Bcl-2高表达联合慢性活跃BCR信号可准确预测双抑制反应。
- 原位异种移植和患者来源异种移植模型证实联合治疗在减轻淋巴瘤负荷方面优于单药。
- 联合治疗有效克服维奈克拉原发性和获得性耐药,可能与依鲁替尼处理下Bcl-XL和Bcl-2A1表达降低有关。
- 瑞士弥漫性大B细胞淋巴瘤队列中约15%患者基于Bcl-2高表达和核NF-κB定位预测对维奈克拉/依鲁替尼联合有反应。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Numerous targeted therapies have been developed for diffuse large B-cell lymphoma, but the results of late-stage clinical trials were mostly disappointing and have led to very few new regulatory approvals. Here, we use single and combinatorial drug response profiling to show that the combined inhibition of the anti-apoptotic protein Bcl-2 and of the tyrosine kinase BTK with the small molecules venetoclax and ibrutinib efficiently kills DLBCL cells in vitro. High Bcl-2 expression due to either BCL2 amplifications or translocations, in conjunction with chronic active BCR signaling accurately predict responses to dual Bcl-2/BTK inhibition. Orthotopic xenotransplantation and patient-derived xenograft models confirm that the combinatorial is superior to single-agent treatment in reducing the lymphoma burden. Combinatorial treatment further efficiently overcomes both primary and acquired resistance to venetoclax, which we could link to reduced expression of the Bcl-2 family members Bcl-XL and Bcl-2A1 under ibrutinib. We found in a Swiss DLBCL cohort that ~15% of patients are projected to respond to the venetoclax/ibrutinib combination based on their high Bcl-2 expression and nuclear NF-κB localization. Our data show that drug sensitivities exposed by drug response profiling can be attributed to specific mutational signatures and immunohistochemical biomarkers, and point to combined Bcl-2/BTK inhibition as a promising therapeutic strategy in DLBCL.
引用
- Bertram K, Leary PJ, Boudesco C, et al. Inhibitors of Bcl-2 and Bruton's tyrosine kinase synergize to abrogate diffuse large B-cell lymphoma growth in vitro and in orthotopic xenotransplantation models. Leukemia. 2021. PMID: 34795418. doi:10.1038/s41375-021-01470-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。